KR20220126787A - Hiv 및 aids의 치료 및 예방 방법 - Google Patents
Hiv 및 aids의 치료 및 예방 방법 Download PDFInfo
- Publication number
- KR20220126787A KR20220126787A KR1020227029968A KR20227029968A KR20220126787A KR 20220126787 A KR20220126787 A KR 20220126787A KR 1020227029968 A KR1020227029968 A KR 1020227029968A KR 20227029968 A KR20227029968 A KR 20227029968A KR 20220126787 A KR20220126787 A KR 20220126787A
- Authority
- KR
- South Korea
- Prior art keywords
- hiv
- administration
- once
- efda
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020257028942A KR20250136420A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294576P | 2016-02-12 | 2016-02-12 | |
| US62/294,576 | 2016-02-12 | ||
| US201662297657P | 2016-02-19 | 2016-02-19 | |
| US62/297,657 | 2016-02-19 | ||
| KR1020217012504A KR20210049201A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
| PCT/US2017/017283 WO2017139519A1 (en) | 2016-02-12 | 2017-02-10 | Methods for treatment and prophylaxis of hiv and aids |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217012504A Division KR20210049201A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257028942A Division KR20250136420A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220126787A true KR20220126787A (ko) | 2022-09-16 |
Family
ID=58057333
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227029968A Ceased KR20220126787A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
| KR1020257028942A Pending KR20250136420A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
| KR1020187025948A Active KR102317570B1 (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
| KR1020217012504A Ceased KR20210049201A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257028942A Pending KR20250136420A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
| KR1020187025948A Active KR102317570B1 (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
| KR1020217012504A Ceased KR20210049201A (ko) | 2016-02-12 | 2017-02-10 | Hiv 및 aids의 치료 및 예방 방법 |
Country Status (37)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | Combination drug therapy |
| US12297224B2 (en) * | 2018-07-02 | 2025-05-13 | Henan Genuine Biotech Co., Ltd. | Crystal form, preparation method, and application of 4'-substituted nucleoside |
| EP3823632B1 (en) * | 2018-07-17 | 2025-10-29 | Merck Sharp & Dohme LLC | Efda in combination with doravirine for use in treating f227c mutated hiv infections |
| JP7530899B2 (ja) * | 2018-12-20 | 2024-08-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎｒｔｔｉ化合物の新規結晶形態 |
| SG11202107145SA (en) | 2019-01-25 | 2021-08-30 | Univ Brown | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders |
| AU2020231934B2 (en) * | 2019-03-06 | 2023-04-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Compounds useful in HIV therapy |
| WO2021021717A1 (en) | 2019-07-27 | 2021-02-04 | Brii Biosciences, Inc. | Adenosine derivative and pharmaceutical composition comprising the same |
| WO2023196832A2 (en) * | 2022-04-06 | 2023-10-12 | Brii Biosciences, Inc. | Pharmaceutical composition and method for treatment of human immunodeficiency virus infections |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0831852B1 (en) * | 1995-06-07 | 2006-11-29 | Emory University | Nucleosides with anti-hepatitis b virus activity |
| EA012844B1 (ru) | 2003-02-19 | 2009-12-30 | Йельский Университет | Аналоги противовирусных нуклеозидов и способы лечения вирусных инфекций, в частности вич-инфекций |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| WO2009126293A2 (en) * | 2008-04-11 | 2009-10-15 | Yale University | Potent chimeric nrti-nnrti bifunctional inhibitors of hiv-1 reverse transcriptase |
| WO2012099630A1 (en) * | 2011-01-20 | 2012-07-26 | University Of Rochester | Compositions and methods for treating or preventing a retrovirus infection |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| CN108289931B (zh) | 2015-09-23 | 2022-10-11 | 默沙东公司 | 4’-取代的核苷逆转录酶抑制剂及其制备 |
| JOP20170038B1 (ar) * | 2016-02-12 | 2021-08-17 | Merck Sharp & Dohme | مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه |
| KR102272235B1 (ko) * | 2016-05-12 | 2021-07-01 | 머크 샤프 앤드 돔 코포레이션 | 항바이러스제의 전달을 위한 약물 전달 시스템 |
| US20190388336A1 (en) * | 2016-06-20 | 2019-12-26 | Merck Sharp & Dohme Corp. | Drug Delivery System for the Delivery of Antiviral Agents |
| WO2019016679A1 (en) * | 2017-07-18 | 2019-01-24 | Viiv Healthcare Company | Combination drug therapy |
| CA3150272A1 (en) * | 2019-08-13 | 2021-02-18 | Merck Sharp & Dohme Corp. | Drug delivery system for the delivery of antiviral agents |
| CN115843259A (zh) * | 2020-05-05 | 2023-03-24 | 默沙东有限责任公司 | 用于递送抗病毒剂和避孕药的药物递送系统 |
| US20230310309A1 (en) * | 2020-08-25 | 2023-10-05 | Merck Sharp & Dohme Llc | Injectable depot compositions for the delivery of antiviral agents |
-
2017
- 2017-02-09 JO JOP/2017/0038A patent/JOP20170038B1/ar active
- 2017-02-10 GE GEAP201715046A patent/GEP20217231B/en unknown
- 2017-02-10 MX MX2018009763A patent/MX390604B/es unknown
- 2017-02-10 MX MX2022002925A patent/MX2022002925A/es unknown
- 2017-02-10 TN TNP/2018/000267A patent/TN2018000267A1/en unknown
- 2017-02-10 UA UAA201809259A patent/UA126375C2/uk unknown
- 2017-02-10 CN CN202110783129.4A patent/CN113509480A/zh active Pending
- 2017-02-10 IL IL260874A patent/IL260874B2/en unknown
- 2017-02-10 AU AU2017217656A patent/AU2017217656B2/en active Active
- 2017-02-10 PL PL17706102.5T patent/PL3413897T3/pl unknown
- 2017-02-10 TW TW112126073A patent/TWI911551B/zh active
- 2017-02-10 JP JP2018541685A patent/JP6810972B2/ja active Active
- 2017-02-10 HR HRP20230935TT patent/HRP20230935T1/hr unknown
- 2017-02-10 MX MX2022002924A patent/MX2022002924A/es unknown
- 2017-02-10 HU HUE17706102A patent/HUE063532T2/hu unknown
- 2017-02-10 DK DK17706102.5T patent/DK3413897T3/da active
- 2017-02-10 FI FIEP17706102.5T patent/FI3413897T3/fi active
- 2017-02-10 ES ES17706102T patent/ES2953535T3/es active Active
- 2017-02-10 WO PCT/US2017/017283 patent/WO2017139519A1/en not_active Ceased
- 2017-02-10 EP EP17706102.5A patent/EP3413897B1/en active Active
- 2017-02-10 CA CA3013473A patent/CA3013473C/en active Active
- 2017-02-10 KR KR1020227029968A patent/KR20220126787A/ko not_active Ceased
- 2017-02-10 NZ NZ745065A patent/NZ745065A/en unknown
- 2017-02-10 CN CN201780010879.XA patent/CN108697727A/zh active Pending
- 2017-02-10 TW TW106104527A patent/TWI822652B/zh active
- 2017-02-10 US US15/430,016 patent/US10537589B2/en active Active
- 2017-02-10 MD MDE20181208T patent/MD3413897T2/ro unknown
- 2017-02-10 EA EA201891814A patent/EA201891814A1/ru unknown
- 2017-02-10 KR KR1020257028942A patent/KR20250136420A/ko active Pending
- 2017-02-10 LT LTEPPCT/US2017/017283T patent/LT3413897T/lt unknown
- 2017-02-10 PT PT177061025T patent/PT3413897T/pt unknown
- 2017-02-10 SI SI201731395T patent/SI3413897T1/sl unknown
- 2017-02-10 GE GEAP202014873A patent/GEP20207190B/en unknown
- 2017-02-10 SG SG11201806783WA patent/SG11201806783WA/en unknown
- 2017-02-10 KR KR1020187025948A patent/KR102317570B1/ko active Active
- 2017-02-10 MY MYPI2018001425A patent/MY197090A/en unknown
- 2017-02-10 RS RS20230656A patent/RS64448B1/sr unknown
- 2017-02-10 KR KR1020217012504A patent/KR20210049201A/ko not_active Ceased
- 2017-02-10 BR BR112018016349A patent/BR112018016349A2/pt not_active Application Discontinuation
-
2018
- 2018-07-27 ZA ZA2018/05073A patent/ZA201805073B/en unknown
- 2018-08-08 NI NI201800083A patent/NI201800083A/es unknown
- 2018-08-08 CL CL2018002150A patent/CL2018002150A1/es unknown
- 2018-08-09 SV SV2018005733A patent/SV2018005733A/es unknown
- 2018-08-10 DO DO2018000183A patent/DOP2018000183A/es unknown
- 2018-08-13 PH PH12018501712A patent/PH12018501712A1/en unknown
-
2019
- 2019-12-11 US US16/710,875 patent/US11337991B2/en active Active
-
2020
- 2020-04-30 AU AU2020202866A patent/AU2020202866B2/en active Active
- 2020-09-11 JP JP2020153037A patent/JP7021314B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015456A patent/JP2022062170A/ja active Pending
- 2022-03-10 AU AU2022201686A patent/AU2022201686B2/en active Active
- 2022-04-08 US US17/658,547 patent/US12171776B2/en active Active
-
2023
- 2023-10-06 JP JP2023174548A patent/JP7559175B6/ja active Active
-
2024
- 2024-11-13 US US18/946,040 patent/US20250073254A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102317570B1 (ko) | Hiv 및 aids의 치료 및 예방 방법 | |
| AU2018239257B2 (en) | HIV post-exposure prophylaxis | |
| HK40054462A (en) | Methods for treatment and prophylaxis of hiv and aids | |
| HK1257347B (en) | Methods for treatment and prophylaxis of hiv and aids | |
| EA042565B1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ ВИЧ И СПИДа | |
| US20220265689A1 (en) | Hiv pre-exposure prophylaxis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |